CoChat

Efficacy and Safety of Elafibranor in Primary Biliary Cholangitis

Open access

The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.

Abstract

Phase 3 trial of elafibranor in PBC with inadequate response or intolerance to UDCA.

Overview

Integrity signals

Registry

Crossref · 10.1056/nejmoa2306185

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

11 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

Show all 33 references

Cited by

See all 314

Metadata

Authors
Kowdley, K. V., Bowlus, C. L., Levy, C., Akarca, U. S., Alvares-da-Silva, M. R., Andreone, P., Arrese, M., Corpechot, C., Francque, S. M., Heneghan, M. A., Invernizzi, P., Jones, D., Kruger, F. C., Lawitz, E., Mayo, M. J., Shiffman, M. L., Swain, M. G., Valera, J. M., Vargas, V., Vierling, J. M., Villamil, A., Addy, C., Dietrich, J., Germain, J.-M., Mazain, S., Rafailovic, D., Taddé, B., Miller, B., Shu, J., Zein, C. O., & Schattenberg, J. M.
Affiliations
  • Universidade Federal do Rio Grande (BR)
  • From Liver Institute Northwest, Seattle (K.V.K.); the Division of Gastroenterology and Hepatology, UC Davis School of Medicine, Sacramento (C.L.B.); Schiff Center for Liver Diseases, University of Miami, Miami (C.L.); the Department of Gastroenterology, Ege University Faculty of Medicine, İzmir, Turkey (U.S.A.); Gastroenterology and Hepatology Division, Hospital de Clinicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil (M.R.A.-S.); Medicina Interna Metabolica, Baggiovara Hospital, Azienda Ospedaliero-Universitaria di Modena and Università di Modena e Reggio Emilia, Modena (P.A.), and the Division of Gastroenterology, Center for Autoimmune Liver Diseases, Department of Medicine and Surgery, University of Milano-Bicocca, and the European Reference Network on Hepatological Diseases (ERN RARE-LIVER), Fondazione IRCCS San Gerardo dei Tintori, Monza (P.I.) — all in Italy; Departamento de Gastroenterología, Escuela de Medicina, Pontificia Universidad Catolica de Chile, Santiago ...
Venue
New England Journal of Medicine
Published
2024-02-29
Volume
390
Issue
9
Pages
795-805
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W4388621682
Cited by
314
References
33
Citations by year
2026: 112 · 2025: 125 · 2024: 76
FWCI
52.53
Type
journal article
Language
en
Open access
Locations
  • New England Journal of Medicine (publishedVersion)
  • PubMed (publishedVersion)
  • BOA (University of Milano-Bicocca) (submittedVersion)
  • Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion)
  • Newcastle University ePrints (Newcastle Univesity)
Funders
  • Ipsen
  • GENFIT
Topics
  • Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
  • Health Sciences › Medicine › Surgery › Pediatric Hepatobiliary Diseases and Treatments
  • Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
Keywords
elafibranor, primary biliary cirrhosis, ursodeoxycholic acid, cholestasis, alkaline phosphatase, pruritus, liver fibrosis, treatment efficacy, drug safety, bile duct destruction, cholestatic liver disease
MeSH terms
Administration, Oral, Alkaline Phosphatase, Bilirubin, Cholagogues and Choleretics, Cholestasis, Double-Blind Method, Gastrointestinal Agents, Humans, Liver Cirrhosis, Biliary, Propionates, Pruritus, Ursodeoxycholic Acid, Treatment Outcome, Chalcones, Peroxisome Proliferator-Activated Receptors, PPAR alpha, PPAR delta

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficacy and Safety of Elafibranor in Primary Biliary Cholangitis. https://app.cochat.ai/papers/10.1056/nejmoa2306185
The paper
Kowdley, K. V., Bowlus, C. L., Levy, C., Akarca, U. S., Alvares-da-Silva, M. R., Andreone, P., Arrese, M., Corpechot, C., Francque, S. M., Heneghan, M. A., Invernizzi, P., Jones, D., Kruger, F. C., Lawitz, E., Mayo, M. J., Shiffman, M. L., Swain, M. G., Valera, J. M., Vargas, V., . . . Schattenberg, J. M. (2024). Efficacy and Safety of Elafibranor in Primary Biliary Cholangitis. New England Journal of Medicine. https://doi.org/10.1056/nejmoa2306185

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.